Solid Biosciences Inc. SLDB
We are a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, which we refer to collectively as our Candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy ("Duchenne"), SGT-212 for the treatment of Friedreich's ataxia ("FA"), SGT-501 for the treatment of Catecholaminergic polymorphic ventricular tachycardia ("CPVT"), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy ("TNNT2 DCM"), and additional assets for the treatment of genetic cardiac and neuromuscular diseases, at different stages of development, with varying levels of investment. We are advancing our diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, our mission is to improve the daily lives of patients living with these devastating diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $8.1M | $13.6M | $0 | $0 | $0 | $0 | $0 |
| R&D | $140.3M | $96.4M | $76.6M | $78.4M | $58.7M | $64.9M | $94.7M | $58.0M | $39.9M | $20.1M |
| SG&A | $38.9M | $33.3M | $27.8M | $28.9M | $27.1M | $21.6M | $24.6M | $17.7M | $15.0M | $5.5M |
| Total operating expenses | $179.2M | $129.7M | $104.3M | $114.5M | $85.9M | $88.4M | $119.3M | $75.7M | $54.9M | $25.6M |
| Operating income | -$179.2M | -$129.7M | -$104.3M | -$106.5M | -$72.3M | -$88.4M | -$119.3M | -$75.7M | -$54.9M | -$25.6M |
| Interest expense | $203.0K | $340.0K | $440.0K | — | — | — | — | — | — | — |
| Pre-tax income | -$174.2M | -$124.6M | -$96.0M | -$86.0M | -$72.2M | -$88.3M | -$117.2M | -$74.8M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$174.3M | -$124.7M | -$96.0M | -$86.0M | -$72.2M | -$88.3M | -$117.2M | -$74.8M | -$52.1M | -$21.5M |
| EPS, basic | -1.99 | -3.06 | -4.83 | -10.10 | -10.14 | -25.50 | — | — | — | — |
| EPS, diluted | -1.99 | -3.06 | -4.83 | -10.10 | -10.14 | -25.50 | -2.91 | -2.25 | -2.88 | -10.14 |
| Shares, diluted (wtd. avg.) | 87.5M | 40.8M | 19.9M | 8.5M | 7.1M | 3.5M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $59.9M | $80.2M | $75.8M | $157.2M | $119.1M | $155.1M | $76.0M | $86.4M | $52.1M | $7.8M |
| Short-term investments | $128.0M | $68.7M | $49.6M | $58.3M | $88.6M | — | $7.5M | $36.1M | $17.0M | — |
| Total current assets | $205.5M | $157.3M | $129.7M | $219.6M | $222.6M | $158.9M | $86.3M | $128.6M | $70.7M | — |
| Property, plant and equipment | $4.2M | $4.7M | $6.6M | $9.7M | $6.5M | $8.2M | $11.6M | $10.4M | $2.4M | — |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M | $171.2M | $103.5M | $139.6M | $76.2M | — |
| Accounts payable | $3.2M | $4.2M | $2.0M | $3.2M | $4.5M | $3.3M | $7.1M | $3.7M | $5.1M | — |
| Total current liabilities | $33.5M | $30.3M | $14.5M | $22.5M | $23.6M | $24.5M | $18.3M | $12.5M | $11.3M | — |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M | $39.1M | $23.4M | $14.4M | $11.3M | — |
| Retained earnings | -$957.8M | -$783.5M | -$658.8M | -$562.7M | -$476.8M | -$404.6M | -$316.3M | -$199.1M | -$124.3M | — |
| Total equity | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M | $132.1M | $80.0M | $125.2M | -$59.3M | -$37.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$156.3M | -$100.0M | -$94.2M | -$98.0M | -$77.8M | -$56.6M | -$92.7M | -$70.2M | -$43.2M | -$20.1M |
| Depreciation and amortisation | — | — | $2.6M | $2.4M | $3.0M | $3.9M | $2.8M | $1.6M | $448.0K | $56.0K |
| Stock-based compensation | $16.9M | $10.5M | $7.6M | $7.5M | $13.4M | $11.6M | $14.2M | $6.0M | $5.3M | $1.5M |
| Capital expenditure | $1.2M | $654.0K | $1.5M | $3.0M | $1.3M | $899.0K | $4.4M | $7.8M | $2.3M | $392.0K |
| Investing cash flow | -$58.5M | -$16.1M | $9.7M | $59.2M | -$91.1M | $6.6M | $24.5M | -$26.8M | $10.4M | -$4.1M |
| Financing cash flow | $194.4M | $122.4M | $3.1M | $74.8M | $135.0M | $128.7M | $57.9M | $131.5M | $77.1M | $3.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-173642.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $13.6M | $8.1M | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$21.5M | -$52.1M | -$74.8M | -$117.2M | -$88.3M | -$72.2M | -$86.0M | -$96.0M | -$124.7M | -$174.3M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |